scholarly journals Rearrangement of the genes for the beta and gamma chains of the T cell receptor is rarely observed in adult B cell lymphoma and chronic lymphocytic leukemia.

1987 ◽  
Vol 80 (4) ◽  
pp. 1209-1214 ◽  
Author(s):  
A C Aisenberg ◽  
B M Wilkes ◽  
J O Jacobson
Keyword(s):  
T Cell ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
T Cell Receptor ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Cell Receptor ◽  
Lymphocytic Leukemia

An (8;14)(q24;q11) translocation involving the T-cell receptor α-chain gene and theMYC oncogene 3′ region in a B-cell lymphoma

1989 ◽  
Vol 1 (1) ◽  
pp. 15-22 ◽  
Author(s):  
James K. Park ◽  
Timothy W. McKeithan ◽  
Michelle M. le Beau ◽  
Mitchell A. Bitter ◽  
Wilbur A. Franklin ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
T Cell Receptor ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Cell Receptor ◽  
Chain Gene ◽  
Α Chain

scholarly journals Development of High-Grade B-Cell Lymphoma Concurrent with T-Cell Chronic Lymphocytic Leukemia in a Dog

2012 ◽  
Vol 74 (5) ◽  
pp. 677-680 ◽  
Author(s):  
Takumi OKAWA ◽  
Hiroko HIRAOKA ◽  
Yuko WADA ◽  
Kenji BABA ◽  
Kazuhito ITAMOTO ◽  
...  
Keyword(s):  
T Cell ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Lymphocytic Leukemia ◽  
High Grade ◽  
Cell Chronic Lymphocytic Leukemia

Alteration of the gene expression profile of T-cell receptor αβ-modified T-cells with diffuse large B-cell lymphoma specificity

Hematology ◽  
2013 ◽  
Vol 18 (3) ◽  
pp. 138-143 ◽  
Author(s):  
Xianfeng Zha ◽  
Qingsong Yin ◽  
Huo Tan ◽  
Chunyan Wang ◽  
Shaohua Chen ◽  
...  
Keyword(s):  
Gene Expression ◽  
T Cells ◽  
T Cell ◽  
B Cell ◽  
T Cell Receptor ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Cell Receptor ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Cerebral aspergillosis in a patient on ibrutinib therapy—A predisposition not to overlook

2018 ◽  
Vol 25 (6) ◽  
pp. 1486-1490 ◽  
Author(s):  
Muhammad Salman Faisal ◽  
Hira Shaikh ◽  
Ahmed Khattab ◽  
Mary Albrethsen ◽  
Salman Fazal
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Rare Complication ◽  
B Cell Lymphoma ◽  
Complete Recovery ◽  
Cell Receptor ◽  
Lymphocytic Leukemia ◽  
B Cell Receptor Signaling

Ibrutinib has revolutionized the treatment of B-cell malignancies since its approval for chronic lymphocytic leukemia. It is also used in mantle cell lymphoma, diffuse large B-cell lymphoma, Waldenstrom’s macroglobulinemia, among others. It is a Bruton’s tyrosine kinase inhibitor that acts on B-cell receptor signaling pathway and predisposes to various infections due to its effects on neutrophils, monocytes and T cells. We present a case of cerebral invasive aspergillosis in a patient being treated with ibrutinib for relapsed chronic lymphocytic leukemia. It was hard to associate the condition to ibrutinib versus the chronic lymphocytic leukemia. The patient was successfully treated with a combination of voriconazole and micafungin, resulting in complete recovery and no residual deficits. This highlights the importance of recognizing the rare complication in those on ibrutinib and initiating the treatment immediately with appropriate antifungal agents to improve prognosis of this potentially fatal condition.

scholarly journals The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia

2016 ◽  
Vol 7 (6) ◽  
pp. 321-329 ◽  
Author(s):  
Valentín Ortíz-Maldonado ◽  
Pablo Mozas ◽  
Julio Delgado
Keyword(s):  
Clinical Trials ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Mitochondrial Pathway ◽  
Therapeutic Agents ◽  
Lymphocytic Leukemia ◽  
Hallmarks Of Cancer ◽  
Lymphoid Malignancies

B-cell lymphoma 2 (BCL2)-type proteins are key regulators of the intrinsic or mitochondrial pathway for apoptosis. Since escape from apoptosis is one the main ‘hallmarks of cancer’, BCL2 inhibitors have emerged as promising therapeutic agents for diverse lymphoid malignancies, particularly chronic lymphocytic leukemia (CLL). Multiple clinical trials have shown efficacy of these agents in patients with relapsed/refractory disease with a favorable toxicity profile. Moreover, some clinical trials indicate that combination with monoclonal antibodies and other novel agents may enhance their effect.

Sign in / Sign up

Export Citation Format

Share Document